Core Insights - The core viewpoint of the news is that Yidu Technology, a leading player in China's AI healthcare industry, has made significant progress across various business segments, including clinical research services, hospital AI construction, innovative drug development support, and health insurance operations, showcasing a strong trend of collaborative development among its diverse business lines. Group 1: Clinical Research Services - Yidu Technology successfully won the bid for the phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops for Shandong Yandu Biotechnology Co., with a total project amount of approximately RMB 55.82 million [2] - The company also secured a project for AI construction at Beijing Cancer Hospital, amounting to RMB 4.88 million, marking the first large model application project at a hospital level, setting a precedent for future large model business expansion [2] Group 2: Innovative Drug Development - In the innovative drug development support sector, the first innovative drug DF-006 developed by Drug Ranch has received approval from the China National Medical Products Administration to conduct phase 1b clinical trials in patients with chronic hepatitis B [3] - Yidu Technology played a crucial role as a service support provider for this project, leveraging its regulatory expertise and efficient project execution to facilitate the successful approval of the clinical trial application [3] Group 3: Health Insurance Operations - As the main operating platform for "Beijing Inclusive Health Insurance," Yidu Technology actively supported the 2025 Financial Education Promotion Week [4] - By the end of August 2025, the "Beijing Inclusive Health Insurance" had processed a total of 419,000 claims, with the highest single claim amount reaching RMB 761,100, and 89% of claims being processed quickly, effectively providing medical coverage for residents of Beijing [4] - The solid advancement of various business segments reflects Yidu Technology's professional capabilities and innovative vitality in the medical AI field, accelerating the synergy of its diverse business operations and laying a solid foundation for future development [4]
医渡科技9月通讯：业务拓展与项目突破双线并进